Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates to treat patients suffering from central nervous system diseases. Co.'s primary product candidate is roluperidone, a compound it is developing for the treatment of negative symptoms in patients with schizophrenia. Co. holds the license to roluperidone from Mitsubishi Tanabe Pharma Corporation with the rights to develop, sell and import roluperidone globally, excluding most of Asia. Co. also has exclusive rights to develop and commercialize MIN-301, a compound for the treatment of Parkinson's disease. We show 41 historical shares outstanding datapoints in our NERV shares outstanding history coverage, used to compute NERV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NERV market cap history over the course of time is important for investors
interested in comparing NERV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NERV versus a peer is one thing; comparing
NERV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NERV can fluctuate over the course of history.
With this page we aim to empower investors researching NERV by allowing them to research the NERV market cap history. |
Free NERV Email Alerts:
Video: The Importance of Market Cap
